Patent or perish? An ethical approach to patenting human genes and proteins

Pharmacogenomics Journal

Volumn 2, Issue 6, 2002, Pages 361-366

  Macer, D R J ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; MESSENGER RNA; PROTEIN;

ACCESS TO INFORMATION; ANIMAL GENETICS; ARTICLE; BIOTECHNOLOGICAL PROCEDURES; DNA SEQUENCE; EXPRESSED SEQUENCE TAG; GENE MUTATION; GOVERNMENT; HUMAN; HUMAN GENETICS; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICINAL PLANT; MORALITY; PATENT; PLANT GENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; SEQUENCE DATABASE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; GENES; GENETICS, MEDICAL; HUMANS; PATENTS; PROTEINS;

ANIMALIA;

EID: 0036986505     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500140     Document Type: Article

References (46)

1. Macer DRJ. Inventions, patents and morality, entry E6-58-09-03. In: Encyclopedia of Life Support Systems. UNESCO, 2002.
2. Kiley TD. Patents on random complementary DNA fragments. Science 1992; 257: 915-918.
3. Knoppers BM. Status, sale and patenting of human genetic materials: an international survey. Nat Genet 1999; 22: 23-25.
4. Thomas SM, Davies ARW, Birtwistle NJ, Crowther SM, Burke JF. Ownership of the human genome. Nature 1996; 380: 387-388.
5. Spranger TM. Legal status and patentability of stem cells in Europe. Biotechnol Law Rep 2002; 21: 105-112.
6. National Academy of Sciences (US). Intellectual Property Rights and Research Tools in Molecular Biology. National Academy Press: Washington DC, 1997.
7. /44/EC Directive on the Legal Protection of Biotechnological Inventions, OJ No. L 213/13 of 30.7.98.
8. Thambisetty S. Understanding morality as a ground for exclusion from patentability under European law. Eubios J Asian Int Bioethics 2002; 12: 46-52.
9. Beyleveld D. Regulating morality through patent law. Critique of the EC Directive. Law Hum Genome Rev 2000; 12: 141-170.
10. Crespi RS. An analysis of moral issues affecting patenting inventions in the Life Sciences: A European perspective. Scie Eng Ethics 2000; 6: 157-180.
11. Macer D. Ethical issues in patenting scientific research. Proceedings of the International Conference of the Council of Europe on Ethical Issues Arising from the Application of Biotechnology, Vol II, Council of Europe, 2000, pp 173-181.
12. Meyers TC, Turano TA, Greenhalgh DA, Waller PRH. Patent protection for protein structures and databases. Nat Struct Biol 2000; 7(Suppl): 950-952.
13. U.S. Congress Office of Technology Assessment, New Developments in Biotechnology. 4. Patenting Life (Washington, D.C., U.S.G.P.O. 1989. OTA-BA-370).
14. Poste G. The case for genomic patenting. Nature 1995; 378: 534-536.
15. Editorial, Public vs. private genomics. Nature 2000; 403: 117.
16. Bobrow M, Thomas S. Patents in a genetic age. Nature 2001; 409: 763-764.
17. Nelkin D, Andrews L. Homo economicus: the commercialization of body tissue in the age of biotechnology. Hastings Center Rep 1998; 28: 30-39.
18. Macer DRJ. Bioethics and biotechnology: what is ethical biotechnology? In: Brauer D (ed.). Modern Biotechnology: Legal, Economic and Social Dimensions, Biotechnology, Vol 12, VCH: Weinheim, Germany, 1995, pp 115-154.
19. Macer D. Public opinion on gene patents, Nature 1992; 358: 272.
20. Macer DRJ. Bioethics for the People by the People.Eubios Ethics Institute: Christchurch, 1994.
21. Hanson MJ. Religious voices in biotechnology. The case of gene patenting. Hastings Center Report 1997; 27(Special Suppl): 1-22.
22. Hoedemaekers R, Dekkers W. Is there a unique moral status of human DNA that prevents patenting? Kennedy Inst Ethics J 2001; 11: 359-386.
23. Universal Declaration on the Human Genome and Human Rights, UNESCO, 1997.
24. Nuffield Council on Bioethics. The Ethics of Patenting DNA. (Nuffield Council on Bioethics: London, 2002) (www.nuffieldbioethics.org).
25. Human Genome Organization, HUGO Statement on Patenting of DNA sequences - In Particular Response to the European Biotechnology Directive-April 2000.
26. http://snp.cshl.org/
27. Eisenberg RS. Genes, patents, and product development. Science 1992; 257: 903-908.
28. Brock DW. Some questions about the moral responsibilities of drug companies in developing countries. Dev World Bioethics 2001; 1: 33-37.
29. Resnik DB. DNA patents and scientific discovery and innovation: assessing benefits and risks. Sci Eng Ethics 2001; 7: 29-62.
30. Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science 1998; 280: 698-701.
31. Barton JH. Reforming the patent system. Science 2000; 287: 1933-1934.
32. Patrinos A, Drell D. The times they are a-changin. Nature 2002; 417: 589-590.
33. Editorial. The people vs patents. New Sci (13 July 2002), 3.
34. Working Group of the UNESCO International Bioethics Committee, Draft Report on the Follow-up of the international Symposium on 'Ethics, Intellectual Property and Genomics', Paris, 29 August 2001. http://www.-unesco.org/ibc/en/reports/DraftRep_IntSymp_Eth- PropInt-Genpdf
35. Commission on Human Rights, Resolution 200/7 (17 August 2000).
36. Macer D. Whose genome project? Bioethics 1991; 5: 183-211.
37. Doha Declaration. Declaration on the TRIPs Agreement and public health, adopted at the Fourth WTO Ministerial Conference, Doha, Qatar, 2001.
38. Powledge F. Patenting, privacy, and the global commons. BioScience 2001; 51: 273-277.
39. Hilgartner S. Acceptable intellectual property. J Mol Biol 2002; 319: 943-946.
40. CBD website, http://www.biodiv.org/doc/meetings/cop/cop-06/official/cop-06-06-en.pdf
41. HUGO Ethics Committee, Statement on Benefit Sharing (April 2000).
42. Resnik DB. Developing drugs for the developing world: an economic, legal, moral, and political dilemma. Dev World Bioethics 2001; 1: 11-32.
43. Daniels N. Social responsibility and global pharmaceutical companies. Dev World Bioethics 2001; 1: 38-41.
44. Jacobsen R. Economic efficiency and the quality of life. J Business Ethics 1991; 10: 201-219.
45. Ferrell O, Fredrick J. Business Ethics. Houghton Mifflin: Boston, 1991.
46. Gold ER, Caulfield TA. The moral tollbooth: a method that makes use of the patent system to address ethical concerns in biotechnology. Lancet 2002; 359: 2268-2270.